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Introduction
Rho family GTPases regulate cytoskeletal dynamics, thereby 
affecting multiple cellular functions including cell motility and 
polarity (Jaffe and Hall, 2005; Boureux et al., 2007). Their acti-
vation is tightly regulated in space and time. Most Rho GTPases 
cycle between an inactive GDP-bound and an active GTP-bound 
form, which interacts with its downstream targets (Vega and 
Ridley, 2008). Altered Rho GTPase activity or expression is im-
plicated in cancer progression (Ellenbroek and Collard, 2007; 
Vega and Ridley, 2008). The Rho family comprises 20 members 
in humans grouped into eight subfamilies (Vega and Ridley, 
2008). The Rho subfamily includes the isoforms RhoA, RhoB, 
and RhoC, which are 84% identical in sequence; most differ-
ences are concentrated near the C terminus (Wheeler and 
Ridley, 2004).
RhoA, RhoB, and RhoC can all induce stress fibers when 
overexpressed, and the Clostridium botulinum exoenzyme C3 
transferase, which modifies all three isoforms, induces loss of 
stress fibers and inhibits cell migration (Aktories and Just, 
2005). However, several lines of evidence indicate that the iso-
forms have different functions. For example, RhoA and RhoC 
localize to the plasma membrane or interact with RhoGDI in the 
cytoplasm, whereas RhoB localizes to endosomal membranes 
because of its unique C-terminal lipid modifications and regu-
lates endosomal trafficking of membrane receptors (Adamson 
et al., 1992; Wheeler and Ridley, 2004; Heasman and Ridley, 
2008).  In  addition,  knockout  mouse  models  indicate  that 
RhoB has a potential tumor suppressor function, whereas RhoC 
is required specifically for metastasis (Liu et al., 2001; Hakem   
et al., 2005). Furthermore, RhoA often inhibits whereas RhoC 
  enhances cancer cell invasion in vitro (Simpson et al., 2004; 
Bellovin et al., 2006), and RhoC is selectively up-regulated 
during epithelial-mesenchymal transition (Dietrich et al., 2009), 
which occurs in some cancers (Thiery, 2002).
Multiple  targets  have  been  identified  for  Rho  proteins 
(Jaffe and Hall, 2005), but it is not clear whether the isoforms 
selectively act through different or common downstream targets 
to mediate specific responses. Where tested, the isoforms gener-
ally bind to the same targets in vitro; for example, both RhoA 
and RhoC can bind to the Rho-associated kinases ROCK1 and 
ROCK2 (Leung et al., 1996; Ishizaki et al., 1997). Recently, 
however, RhoC but not RhoA or RhoB has been suggested to 
bind specifically to the formin FMNL2 (Kitzing et al., 2010). 
S
everal studies suggest that RhoA and RhoC, de-
spite their sequence similarity, have different roles 
in cell migration and invasion, but the molecular 
basis for this is not known. Using RNAi, we show that 
RhoA-depleted  cells  became  elongated  and  extended 
multiple Rac1-driven narrow protrusions in 2D and 3D 
environments, leading to increased invasion. These pheno-
types were caused by combined but distinct effects of the 
Rho-regulated kinases ROCK1 and ROCK2. Depletion of 
ROCK2 induced multiple delocalized protrusions and 
reduced migratory polarity, whereas ROCK1 depletion   
selectively led to cell elongation and defective tail retrac-
tion. In contrast, RhoC depletion increased cell spread-
ing and induced Rac1 activation around the periphery in 
broad lamellipodia, thereby inhibiting directed migration 
and invasion. These effects of RhoC depletion are medi-
ated by the formin FMNL3, which we identify as a new 
target of RhoC but not RhoA. We propose that RhoA 
contributes  to  migratory  cell  polarity  through  ROCK2-
mediated suppression of Rac1 activity in lamellipodia, 
whereas  RhoC  promotes  polarized  migration  through 
FMNL3 by restricting lamellipodial broadening.
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Videos 1 and 2). In contrast, RhoA-depleted cells became elon-
gated by extending long narrow protrusions in multiple direc-
tions, often from both ends of their long axis. Protrusions were 
also frequently observed along the elongated lateral sides of 
cells, and RhoA-depleted cells had more protrusions, which per-
sisted for longer at the same position than those of control cells 
(Fig. 1 D, Fig. S3 A; Video 3). This was true both for lateral 
protrusions and protrusions at elongated tips. Multiple small 
protrusions were also observed in RhoA-depleted cells during 
spreading (Fig. S2 B and Video 4). RhoC-depleted cells had 
markedly different membrane dynamics. They often had broad 
lamellipodia that sometimes spread around most of the cell 
periphery. These showed dynamic regions of membrane ruf-
fling but little net movement of the cell edge (Fig. 1, A and C; 
and Videos 1–3). These results indicate that RhoA is normally 
required to limit the number of protrusions, whereas RhoC 
  restricts lamellipodial broadening.
Both RhoA and RhoC silencing reduced migration speed 
(Fig. 1 E) but through different mechanisms reflecting their 
effects on lamellipodia. RhoA-depleted cells extended narrow 
protrusions simultaneously in two or more opposing directions, 
resulting  in  reduced  net  movement,  whereas  RhoC-depleted 
cells with the spread phenotype were often unable to polarize 
(Video 1). However, RhoA-depleted cells underwent chemo-
taxis as efficiently as control cells with a similar persistence 
(Fig. 1 F and Video 5). They were still elongated but pro-
truded more frequently toward the source of chemoattractant 
and preferentially elongated in the gradient direction (Fig. 1 G 
and Fig. S2 C). RhoC-depleted cells however migrated less ef-
ficiently toward the chemoattractant with reduced persistence 
(P < 0.005) and lower mean speed (P < 0.001; Fig. 1, E and F; 
Fig. S2 C; and Video 5). RhoC-depleted cells often had one or 
more abnormally extended and broad lamellipodia that split   
frequently (Fig. 1 G, Fig. S2 C, and Video 6), which is consis-
tent with our observation that they have a defect in restricting 
lamellipodial broadening. This could be responsible for their 
reduced persistence.
RhoA depletion promotes invasion
RhoC is often required for cancer cell invasion, whereas re-
sults with RhoA vary depending on the system and cell type 
(Simpson et al., 2004; Bellovin et al., 2006). We investigated 
whether the effects of RhoA and RhoC on migratory polarity 
and lamellipodial distribution in 2D could contribute to cancer 
cell invasion in 3D. Cancer cells often have different morpholo-
gies in 3D environments compared with 2D (Sahai and Marshall, 
2003; Sahai, 2005). The morphology of PC3 cells seeded on top 
of a thick 3D Matrigel layer was similar to that in 2D: RhoA- 
depleted cells were more elongated and RhoC-depleted cells 
were spread (Fig. S2 D).
To observe the morphology of cells during directed inva-
sion, we used MDA-MB-231 cells in a 3D invasion assay in 
Matrigel.  RhoA-depleted  cells  extended  very  elongated  pro-
trusions and invaded the Matrigel more than control or RhoC-
depleted cells (Fig. 2). Cortactin is a cytoskeletal protein that 
localizes in invading protrusions (Weaver, 2008). We observed 
enrichment of cortactin relative to F-actin at the invasive cell 
Here we show that RhoA and RhoC have very different func-
tions in regulating the localization of active Rac1, lamellipodial 
dynamics, cell morphology, migration, and invasion. We demon-
strate that they act through different downstream targets—ROCKs 
and FMNL3, respectively—to mediate their distinct effects.
Results and discussion
RhoA and RhoC have different effects on 
cell morphology
To compare the effects of RhoA and RhoC on cell morphology, 
we used siRNA-mediated knockdown in PC3 prostate cancer 
cells  and  MDA-MB-231  breast  cancer  cells  (Fig.  S1, A–C). 
RhoA or RhoC knockdown did not affect the expression of the 
other isoform, but RhoA and to a lesser extent RhoC knockdown 
induced RhoB up-regulation, which is consistent with previous 
observations (Ho et al., 2008). RhoB levels were also increased 
by C3 transferase, which indicates that it is reduced RhoA and 
RhoC  activity  that  induces  RhoB  up-regulation  (Fig.  S1  B). 
RhoB knockdown did not affect RhoA or RhoC levels. Down-
regulation of each protein led to a decrease in the respective   
levels of active GTP-bound RhoA, RhoB, or RhoC (Fig. S1 A).
RhoA-depleted cells had an elongated cell shape com-
pared with the siRNA control-treated cells, whereas RhoC 
depletion increased cell spread area (Fig. 1, A and B; Fig. S1 D; 
and Video 1). These phenotypes could be rescued by low-level 
expression of siRNA-resistant RhoA or RhoC (Fig. S1, E and 
F). C3 transferase–treated cells became highly elongated, and 
were thus most similar to RhoA-depleted cells (Fig. S1 G). 
These changes in morphology were confirmed with three dif-
ferent siRNAs (two are shown) and were similar in PC3 cells, 
MDA-MB-231 cells, and DU145 and LnCAP prostate cancer 
cell lines, which demonstrates that they are not cell type specific 
(Fig. S1 H and not depicted). Moreover, similar phenotypes 
were observed when cells were seeded on Matrigel-coated tis-
sue culture plastic or uncoated plastic, and are thus not depen-
dent on the extracellular matrix composition. The altered shapes 
of Rho isoform-depleted cells were not caused by a change in 
cell size or volume (not depicted), nor did Rho depletion lead to 
defects in cytokinesis, as indicated by the lack of multinucleate 
cells (Fig. 1 and Fig. S2 A).
The effect of RhoA depletion on cell morphology was not 
caused by RhoB up-regulation, as cells cotransfected with RhoA 
and RhoB siRNAs had a phenotype similar to that of RhoA de-
pletion alone, whereas RhoB depletion alone led to a reduced 
cell spread area (Fig. S2 A). In addition, increased RhoB expres-
sion was also induced by RhoC suppression yet the phenotype 
of RhoA- and RhoC-depleted cells was very different.
RhoA and RhoC have different effects  
on distribution of lamellipodia and  
cell migration
To investigate how RhoA and RhoC depletion had different 
effects on cell shape, we analyzed cells by time-lapse micros-
copy. PC3 cells migrated by extending dynamic F-actin–rich 
protrusions, and frequently formed new protrusions and re-
tracted old protrusions to change direction (Fig. 1, A and C; and 657 RhoA and RhoC targets in migration and invasion • Vega et al.
Figure 1.  RhoA and RhoC have different effects of cell morphology and directional migration. PC3 cells were transfected with indicated siRNAs. (A) Cell 
morphology after siRNA transfection or C3 transferase treatment. Arrows indicate RhoC-depleted cells with increased spread area. (B) F-actin in cells on 
Matrigel. Boxed regions are shown at higher magnification below. (C) Images from movies of GFP–-actin–expressing cells. Arrows indicate lateral pro-
trusions. (D) Protrusion dynamics. Boxed regions on top are shown from movie frames (1 frame/min) in the bottom panels (boxed regions). (E) Migration 
speed. (F) Forward migration index (FMI) in a chemotaxis assay. *, P < 0.001. (G) Cell images during chemotaxis. White arrows indicate broader lamel-
lipodia in RhoC-depleted cells. Black arrows: show gradient direction. Bars: (A) 40 µm; (B, C, D, and G) 20 µm.JCB • VOLUME 193 • NUMBER 4 • 2011   658
or RhoC knockdown (Fig. 3 D), corroborating the Rac1 activ-
ity pull-down results. Thus RhoA and RhoC regulate where 
Rac1 is active rather than how much is active. RhoA suppresses 
Rac1 activity to limit the number of protrusions, whereas RhoC 
  restricts spreading of Rac1 activity along the membrane, thereby 
regulating lamellipodial broadening. The variation in cell mor-
phology and behavior within the PC3 population (Fig. 1 and 
Video 1) could reflect cell-intrinsic differences on RhoA and 
RhoC activity.
ROCK1 and ROCK2 make different 
contributions to RhoA-regulated 
morphology and migration
The Rho-associated protein kinases ROCK1 and ROCK2 are 
major mediators of Rho signaling and are best known as regu-
lators of myosin light chain phosphorylation and actomyosin con-
tractility (Riento and Ridley, 2003). Both RhoA and RhoC can 
bind to ROCKs but whether they are preferentially used by one 
Rho isoform is not known (Sahai and Marshall, 2002; Riento 
and Ridley, 2003). ROCK function is usually studied with 
chemical inhibitors such as Y-27632, which do not discrimi-
nate between ROCK1 and ROCK2 and target other kinases, at 
least in vitro (Bain et al., 2007). Different functions for ROCK1 
and ROCK2 have been described using RNAi in fibroblasts 
(Yoneda et al., 2005, 2007). We used siRNAs to deplete ROCK1 
or ROCK2 to determine if the phenotypes of RhoA or RhoC-
depleted cells could be attributed to a specific ROCK isoform 
(Fig. S3 A). ROCK1 and ROCK2 were expressed similarly in 
PC3 cells (Fig. S3 A). ROCK1 but not ROCK2 suppression in-
duced cell elongation, similar to RhoA knockdown but clearly 
distinct from RhoC knockdown (Fig. 4, A and B).
However, in contrast to RhoA depletion, ROCK1-depleted 
cells had fewer small F-actin–rich protrusions, and the cell 
nucleus was predominantly localized in the first third of the cell 
body (in 70% of migrating cells, whereas in RhoA-depleted 
cells it was in the central third in 80% of cells). ROCK1-
depleted cells also had a long tail, indicative of a tail retraction 
defect (63.5 ± 6% of cells). This phenotype was similar to that 
observed with the ROCK inhibitor Y-27632 (85 ± 4% of cells 
front particularly for RhoA knockdown cells, indicating the 
invasive nature of the protrusions (Fig. 2 B). Similar results were 
observed when a collagen I/Matrigel mix was used (Fig. S2 E). 
The elongated and protrusive phenotype of RhoA-depleted cells 
therefore correlates with an increase in invasive behavior.
RhoA and RhoC have different effects on 
Rac1 activity localization
Despite the large changes in shape induced by RhoA or RhoC 
depletion, there was no difference in the expression or total 
activity of Rac1 (Fig. S2, G and H). Nevertheless, Rac1 was 
  required for the dynamic protrusions in RhoA-depleted cells: 
cells depleted of both Rac1 and RhoA completely lacked 
actin-rich protrusions both at the ends and along the lateral 
edges (Fig. 3 A). Instead, cells had extensive filopodia along 
edges and at protrusion ends, in similar positions to where   
lamellipodia were observed after RhoA depletion alone. Rac1 
depletion alone also led to an increase in filopodia (Fig. 3 A), 
perhaps because Cdc42-induced filopodia are more apparent   
after Rac inhibition (Nobes and Hall, 1995).
We postulated that the differences in distribution and dy-
namics of lamellipodia in RhoA- versus RhoC-depleted cells 
could reflect changes in where Rac1 was active. We therefore 
investigated the localization of active Rac1 by live multiphoton 
fluorescence lifetime imaging microscopy (FLIM) using a Rac1 
Raichu biosensor (Itoh et al., 2002; Makrogianneli et al., 2009). 
The biosensor localized mainly at the plasma membrane and 
did not induce any discernable morphological changes in PC3 
cells (Fig. 3 B). In control cells, Rac1 activity was not strongly 
enriched at the periphery, but was observed sporadically in cen-
tral regions of cells (Fig. 3 B and Videos 7 and 8), which might 
correspond to areas of dorsal protrusion and/or regions of sub-
stratum adhesion. In RhoA-depleted cells, Rac1 activity was 
significantly enriched at sites of membrane protrusive activity 
compared  with  nonprotruding  areas,  including  the  lateral 
protrusions (Fig. 3 C). In contrast, Rac1 activity in RhoC-
depleted cells was more broadly distributed around the periph-
ery (Fig. 3 B), which is consistent with the broad lamellipodia.   
Total Rac1 biosensor activity per cell was not altered by RhoA 
Figure 2.  RhoA knockdown promotes invasive protrusions. (A) 3D invasion (ORIS assay) of siRNA-transfected MDA-MB-231 cells into Matrigel. “No inva-
sion”: stopper removed at the end of assay. Bars, 100 µm. (B) Maximum intensity projection confocal images of F-actin, cortactin, and DAPI-stained cells 
at the invading front from A. Boxed areas are shown at higher magnification (bottom). Bars: (top) 40 µm; (bottom) 20 µm.659 RhoA and RhoC targets in migration and invasion • Vega et al.
resistant to human siRNAs, rescued these siRNA morphology 
phenotypes (Fig. S3 C; note that high-level ROCK1/ROCK2 
expression induced cell contraction, as expected).
Interestingly, simultaneous knockdown of ROCK1 and 
ROCK2 induced a phenotype very similar to RhoA depletion 
(Fig. 4, A and B): cells were elongated with actin-rich protru-
sions at both ends and along lateral edges, and the nucleus was 
centrally localized. Each ROCK therefore has a distinct role 
downstream of RhoA, and the morphology of RhoA-depleted 
cells reflects a combination of ROCK1 and ROCK2 functions. 
Neither ROCK1 nor ROCK2 depletion phenotypes resembled 
with elongated tails; Fig. 4, A and B; and Fig. S3 B). In con-
trast, ROCK2-depleted cells were not elongated and did not 
have a strong tail retraction defect (30.7 ± 6% of cells with 
elongated tails compared with 25 ± 6% of control cells) and in-
stead frequently had multiple thin protrusions, each with a ruf-
fling tip, distributed around the cell perimeter (Fig. 4, A and B;   
and Fig. S3 B). This was not observed in cells treated with 
Y-27632 or another ROCK inhibitor HA-1077 (Fig. 4 A and not 
depicted). This indicates that Y-27632 predominantly acts on 
the ROCK1 isoform in cells, as suggested previously (Darenfed   
et al., 2007). Low-level expression of mouse ROCK1 or ROCK2, 
Figure 3.  RhoA inhibits Rac1-driven protrusive activity. (A) F-actin distribution in PC3 cells after transfection with siRNAs. Boxed regions are shown at 
higher magnification on the right. Bars, 20 µm. (B) FLIM images from PC3 cells cotransfected with the Rac1 biosensor and indicated siRNAs. Higher Rac1 
activity is shown in “warmer” colors. Bars, 10 µm. (C, top) Kymographs of boxed regions in B: protruding membrane region (1) and control nonprotruding 
region (2); 1 frame/min (20 min), t = time. (C, bottom) Graph of threshold relative Rac1 activity values in protruding and control regions; **, P < 0.01. 
(D) Mean total Rac1 biosensor lifetime of cells transfected with the indicated siRNAs. Error bars indicate ± SEM.JCB • VOLUME 193 • NUMBER 4 • 2011   660
were  embedded  in  Matrigel.  They  mostly  formed  spherical 
groups of cells with cell–cell interactions (Fig. 4 D), in contrast 
to their single cell morphology in 2D. The morphology of can-
cer cell groups in 3D is indicative of their invasive potential and 
tumorigenicity (Kenny et al., 2007). Groups of RhoA-depleted 
cells had a more disorganized morphology with multiple dynamic 
extensions  compared  with  control  or  RhoC-depleted  cells 
(Fig. 4, D and E; and not depicted). Again, simultaneous 
ROCK1 and ROCK2 depletion induced a phenotype most simi-
lar to RhoA suppression (Fig. 4 E). RhoA-depleted cells also 
had an elongated morphology when embedded in a collagen   
I/Matrigel mix (Fig. S2 F).
that of RhoC suppression, thus it is unlikely that RhoC acts 
through ROCK1 or ROCK2 to regulate cell morphology in 
this context.
To determine whether the different effects of ROCK iso-
forms on 2D migration were similar in 3D invasion, PC3 cell 
invasion  through  Matrigel-coated  transwells  was  analyzed. 
RhoA suppression increased invasion, whereas RhoC silencing 
reduced invasion (Fig. 4 C). As a control, RhoB depletion did 
not  affect  invasion.  Only  the  simultaneous  knockdown  of 
ROCK1 and ROCK2 increased invasion, which is consistent 
with both being required for RhoA-mediated responses. To ana-
lyze the effects of ROCKs on morphology in 3D, PC3 cells 
Figure 4.  ROCK1 and ROCK2 regulate different aspects of the RhoA morphological response. (A) F-actin distribution in PC3 cells after transfection with 
the indicated siRNAs or ROCK inhibitor Y-27632 treatment. Boxed regions are shown at higher magnification on the right. Bars, 20 µm. (B) Elongation of 
PC3 cells. (C) Transwell invasion assay. (D) PC3 cells embedded in Matrigel stained for F-actin (gray) and nuclei (DAPI; blue). Enlarged views of the boxed 
regions are shown below. Bars, 20 µm. (E) Quantification of cell groups (see D) with more than two F-actin–rich protrusions. (F) Forward migration index 
(FMI) of PC3 cells in a chemotaxis assay. **, P < 0.001; *, P < 0.01. Graphs show pooled results from experiments performed with at least two different 
siRNAs for each gene as indicated in Materials and methods. Error bars indicate mean ± SEM.661 RhoA and RhoC targets in migration and invasion • Vega et al.
the formin family protein FMNL2 is a RhoC effector (Kitzing   
et al., 2010), whereas FMNL1 has been reported as a Cdc42 
effector (Seth et al., 2006). We therefore investigated the effects 
of knocking down FMNL proteins on PC3 cell morphology 
(Fig. 5 A). Depletion of each protein induced a distinct pheno-
type. FMNL2 depletion did not resemble that of RhoC deple-
tion but instead led to an increase in small ruffling protrusions, 
whereas FMNL1 and FMNL3 knockdown cells had an increased 
spread area, broad lamellipodia, and unpolarized morphol-
ogy, resembling the effect of RhoC but not RhoA depletion. 
  Expression of GFP-FMNL3 in FMNL3 knockdown cells res-
cued the increased spreading and broad lamellipodia (Fig. S3 H). 
When RhoC and each FMNL protein were depleted simulta-
neously, either a mixed or an additive phenotype was observed 
with FMNL2 and FMNL1, respectively, but no change was ob-
served with FMNL3, which suggests that RhoC and FMNL3 act 
in the same pathway (Fig. 5 A). Down-regulation of FMNL3 
also impaired invasion of PC3 cells through Matrigel, which in-
dicates that it could contribute to RhoC signaling in promoting 
invasion (Fig. 5 B). Knockdown of FMNL1 or FMNL3 together 
with RhoA also induced large broad lamellipodia (Fig. S3 I); 
thus, the broad lamellipodium phenotype dominates over nar-
row protrusions.
To test if FMNL3 was indeed a new RhoC-specific target, 
we tested its ability to bind to recombinant Rho proteins. FMNL3 
bound to constitutively active GST-RhoC but not RhoA (Fig. 5 C). 
This was true for both N- and C-terminal GFP-tagged FMNL3 
(Fig. S3 J). GFP-FMNL3 localized in actin-rich protrusions, 
and its expression inhibited the broad lamellipodium phenotype 
induced by RhoC knockdown (Fig. 5 D). Together, these re-
sults indicate that FMNL3 acts downstream of RhoC to restrict 
lamellipodial broadening. In contrast, FMNL2-GFP did not bind 
GST-RhoC or RhoA in vitro (Fig. S3 J). This, together with 
the knockdown phenotype, indicates that FMNL2 is not likely 
to act downstream of RhoC under these conditions.
Several formins are known to stimulate the nucleation and 
elongation of actin filaments, thereby contributing to cell motility, 
cytokinesis, and tissue morphogenesis (Chesarone et al., 2010). 
Not much is known about the function of FMNL3, but one study 
identifies it as being down-regulated in cells with reduced tu-
morigenic capacity (Martín-Rufián et al., 2006). It was also 
identified as overexpressed in a highly motile subpopulation of 
melanoma cells in vivo (Pinner et al., 2009). This is consistent 
with a role for FMNL3 downstream of RhoC in promoting can-
cer progression.
Our results show that the closely related Rho GTPases 
RhoA  and  RhoC  have  different  effects  on  cell  morphology, 
  migration, and invasion by acting through different downstream 
targets. We identify for the first time a new RhoC-specific target, 
the formin FMNL3, involved in cancer cell invasion. RhoA de-
pletion leads to elongated cells that extend narrow Rac1-driven 
protrusions in multiple directions in both 2D and 3D environ-
ments, stimulating invasion, and only migrate persistently when 
exposed to a gradient of chemoattractants. In contrast, RhoC-
depleted cells spread with broad lamellipodia, and have reduced 
invasion and migrational persistence even during chemotaxis. 
These results could explain their opposing roles in tumor cell 
The different roles of ROCK1 and ROCK2 downstream of 
RhoA could reflect differential localization in cells. We have not 
been able to detect endogenous ROCK1 or ROCK2 with the anti-
bodies available. GFP-ROCK1 expressed at low levels showed a 
uniform distribution on the plasma membrane (Fig. S3 C). It is 
possible that active ROCK1 is preferentially localized to tails, 
but so far there is no method to localize active ROCK proteins. 
RFP-ROCK2  was  enriched  in  protrusive  areas  in  control  or 
RhoA knockdown cells, which is consistent with a role in regu-
lating protrusion.
The observation that ROCK2-depleted cells had unpolar-
ized protrusive activity implies that ROCK2 normally acts to 
suppress Rac1 activation in protrusions. RhoA is active at the 
front of lamellipodial protrusions (Pertz et al., 2006; Machacek 
et al., 2009; Heasman et al., 2010), and it could therefore locally 
inhibit Rac in this region through ROCK2. When RhoA or ROCK2 
levels are reduced, Rac1 can be active in more areas because of a 
lack of RhoA/ROCK2-mediated suppression, leading to multiple 
protrusions. In contrast, ROCK1 function appears to be restricted 
to tail retraction. Some RhoA-depleted cells transiently showed 
a tail retraction defect, but this phenotype was much stronger 
in ROCK1-depleted cells. RhoA is transiently activated in tails 
before retraction (Pertz et al., 2006; Heasman et al., 2010). The 
migratory phenotype of RhoA-depleted cells therefore reflects a 
combination of decreased ROCK1-mediated tail retraction and 
ROCK2 inhibition of Rac1-driven protrusions. The enhanced 
ability of RhoA/ROCK-depleted cells to invade through Matrigel 
correlates with their elongated morphology, which based on our 
results is likely to reflect increased Rac1 activation in the long 
invasive protrusions. This could be associated with production of 
matrix-degrading proteases required for invasion (Sahai, 2005).
ROCK2 regulates directional migration
We next investigated whether the distinct morphological pheno-
types observed after ROCK1 or ROCK2 depletion correlated with 
different effects on cell migration behavior. Neither ROCK1 nor 
ROCK2  affected  migration  speed,  but  in  chemotaxis  assays 
ROCK2-  but  not  ROCK1-depleted  PC3  cells  migrated  with 
  reduced persistence (forward migration index) compared with con-
trol cells, which indicates a specific involvement of ROCK2 in 
directional migration (Fig. 4 F and Fig. S3 D).
Although ROCK2 and RhoC knockdown both reduced 
directional migration (Fig. 1 F and Fig. 4 F), they act through 
different mechanisms: RhoC-depleted cells have broad lamel-
lipodia whereas ROCK2-depleted cells have narrow protrusions 
(Fig. S3 E). Interestingly, RhoC suppression abolished the mul-
tiple small protrusions in ROCK2-depleted cells (Fig. S3 F), and 
instead cells were spread, often with broad lamellipodia, similar to 
RhoC depletion alone. Thus the function of RhoC in restricting 
lamellipodial broadening is required even in cells with multiple 
small protrusions.
RhoC acts through FMNL3 to regulate cell 
morphology and invasion
Given that the phenotype of ROCK-depleted cells did not re-
semble RhoC suppression, we tested other Rho partners to iden-
tify a potential target for RhoC. It was recently suggested that JCB • VOLUME 193 • NUMBER 4 • 2011   662
293T cells were grown in DME media supplemented with 25 mM Hepes 
and 2 mM glutamine, 10% FCS, 100 µg/ml streptomycin, and 100 U/ml 
penicillin.  The  following  antibodies  were  used:  RhoA  (clone  26C4,   
sc-179), RhoB (119, sc-180) and RhoC (C-16, sc-12116), GFP (FL, sc-
8334), and GST (B14, sc-138; all from Santa Cruz Biotechnology, Inc.). 
Also used were ROCK1 K-18 (sc-6056; Santa Cruz Biotechnology), mouse 
monoclonal ROCK1 (No. 611136; BD), ROCK2 C-20 (sc-1851; Santa 
Cruz Biotechnology, Inc.), mouse monoclonal ROCK2 (No. 610623; BD), 
Rac1 23A clone (No. 05-389; Millipore), mouse monoclonal anti-cortactin 
clone 4F11 (No. 05-180; Millipore), -tubulin DM1A clone (T6199; Sigma- 
Aldrich), and rabbit polyclonal extracellular signal–regulated kinase (ERK), 
invasion. RhoA via ROCKs would inhibit Rac1-dependent pro-
trusion required for invasion, whereas RhoC acting via FMNL3 
would promote this process.
Materials and methods
Cell lines and reagents
PC3 prostate cancer cells were grown in RPMI containing 25 mM Hepes 
and 2 mM glutamine supplemented with 10% FCS, 100 µg/ml strepto-
mycin, and 100 U/ml penicillin. MDA-MB-231 breast cancer cell line and 
Figure 5.  RhoC acts through FMNL3 to regulate cell shape and invasion. (A) F-actin in PC3 cells after transfection with indicated siRNAs. Bar, 20 µm. 
(B) Transwell invasion assay with PC3 cells; invasion is relative to siControl. (C) GST-RhoA/C-V14 pull-down with lysates from 293T cells expressing GFP-
FMNL3. MW, molecular weight markers. (D) F-actin and GFP localization in PC3 cells transfected with the indicated siRNAs and either GFP-FMNL3 or GFP 
alone. White asterisks indicate GFP-FMNL3 cells. The graph on the right shows quantification of GFP-positive cells with broad lamellipodia; *, P < 0.05. 
Error bars indicate mean ± SEM.663 RhoA and RhoC targets in migration and invasion • Vega et al.
from at least four different experiments using at least two different siRNAs 
for each gene were quantified and results were pooled in graphs. Chemo-
taxis and persistence were analyzed using the ImageJ Manual tracking 
and Chemotaxis tool plugins. Further two-sample comparison of migration 
velocity and persistence analysis was performed using the Mathematica 
“Chemotaxis_tests_M6 notebook” developed by G.A. Dunn (King’s College 
London; parameters used for motility analysis: t=8, TR = 4; Zicha et al., 
1997). These data were summarized in a rose plot that is a circular histo-
gram showing the frequency of cell tracks with directions lying within each 
20° interval. It displays the mean direction as a red arrow and the 95% 
confidence interval as a green sector when there is significant directional 
clustering. The Rayleigh test for unimodal clustering of directions (Mardia 
and Jopp, 2000) and the Moore rank test (Moore, 1980) were then ap-
plied to the data and a P  0.01 was chosen as the criterion for rejecting 
the null hypothesis of random directionality.
Immunofluorescence, confocal microscopy, and cell shape analysis
Cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% 
Triton X-100 in PBS, and blocked with 1% BSA in PBS. Alexa fluor phalloidin 
(wavelengths 480 nm or 543 nm; Invitrogen) was used for F-actin visual-
ization, and DAPI was used for nuclear staining. Confocal images were 
acquired with an inverted confocal microscope (LSM 510; Carl Zeiss) using 
40× (1.2 NA) or 63× (1.4 NA) objective lenses. Images are from cells 
fixed 72 h after transfection unless indicated. Images show condition with a 
single siRNA but the same results were obtained with different siRNAs. Mor-
phology analysis was performed using MetaMorph or Cell profiler software 
(Carpenter et al., 2006) from F-actin–stained fluorescence images. In brief, 
this involved segmentation of the images to obtain cell shape and area 
measurements from the corresponding thresholded objects. More than 100 
cells from at least three different experiments were analyzed. The elongation 
factor is defined as the ratio between the major axis and the minor axis of 
the cell (1 = rounded, >1 = more elongated). The shape factor is calculated 
as 4A/p2, where A = area and p = perimeter (1 = circle, <1 = more elon-
gated). Cells with broad lamellipodia (Fig. 5 D) were defined as cells with 
a flattened membrane extension with a narrow lamellipodium around all or 
part of the cell perimeter, as described for RhoC knockdown cells.
FLIM
Rac1 activity was localized with the Rac1 Raichu biosensor modified by 
M. Keppler (King’s College London) to express GFP and mRFP as the donor 
and acceptor fluorophores, respectively (Itoh et al., 2002; Makrogianneli 
et al., 2009). PC3 cells were transfected with the indicated siRNAs and 
seeded on a SmartSlide microincubator chamber (WaferGen Biosystems) 
after 24–36 h. After a further 24 h, cells were transfected with the expres-
sion plasmid encoding the Rac1 Raichu biosensor and incubated for 18 h. 
All FLIM measurements were performed at 37°C on a modified multiphoton 
microscopy system as described previously (Peter et al., 2005) with a Ti:
sapphire Chameleon laser (Coherent, Inc.) tuned to 890 nm. A 510 ±   
10 nm band-pass filter (Chroma Technology Corp) was used in the detector 
channel. Laser power was adjusted to give mean photon counting rates of 
the order of 10
4–10
5 photons/s (0.0001–0.001 photons/excitation event) 
and with peak rates approaching 10
6 photons/s, below the maximum 
counting rate afforded by the time-correlated single photon counting elec-
tronics to avoid pulse pile-up.
Each FLIM image was acquired over 44 s at low excitation power to 
achieve sufficient photon statistics for fitting while avoiding either pulse 
pile-up and keeping photobleaching to a minimum. The imaging interval 
per cell was 60 s and the total imaging period was at least 20 min. Analy-
sis for time-resolved data was performed essentially as described previ-
ously (Peter et al., 2005). The multiphoton intensity images were thresholded 
to remove the background autofluorescence and areas of the cell that 
did not have sufficient photon counts for fitting. To better visualize the intra-
cellular fluorescence lifetime changes, cell images were normalized by the 
mean fluorescence lifetime of the cell of interest and pseudocolored with a 
rainbow look-up table, in which warmer color represents areas with higher 
than average Rac1 activity (lower fluorescence lifetimes) and colder color 
areas with lower Rac1 activity. Total mean lifetime over each whole cell in 
each condition was calculated from still images.
For analysis of Rac1 activity in protruding areas, kymographs of 30 × 
10 pixel regions on protruding membrane areas or control nonprotruding 
areas in RhoA knockdown cells were plotted from the normalized lifetime 
images. Relative lifetimes were threshold as indicated and the relative per-
centage of pixels within the threshold during the movie was calculated for 
17 regions per condition in eight different cells from different experiments. 
Protruding areas were identified from the membrane dynamics in the GFP 
intensity images.
K-23 (sc-94; Santa Cruz Biotechnology). Secondary HRP-labeled antibodies 
were from GE Healthcare (anti–mouse and anti–rabbit) or Santa Cruz Bio-
technology, Inc. (anti–goat). Cell-permeable C3 transferase (Cytoskeleton) 
was used at 1.1 µg/ml for 6 h. The ROCK inhibitor Y-27632 (EMD) was 
used at 5 µM for 12 h. Protease inhibitor cocktail (complete) was from Roche 
and Phosphatase inhibitor cocktail II and IV were from EMD. The EGFP–
-actin construct has been described previously (Ballestrem et al., 1998).
Transfections and Western blotting
All siRNAs were from Dharmacon (Thermo Fisher Scientific): siRhoA-1   
(5-AUGGAAAGCAGGUAGAGUU-3),  siRhoA-2  (5-GAACUAUGUGG-
CAGAUAUC-3), siRhoA-3 (5-CGACAGCCCUGAUAGUUUA-3), siRhoB-1 
(5-CAUCCAAGCCUACGACUAC-3), siRnoB-2 (5-GCAUCCAAGCCUA-
CGACUA-3), siRhoB-3 (5-GCAUCCAAGCCUACGACUA-3), siRhoC-1 
(5-AUAAGAAGGACCUGAGGCA-3), siRhoC-2 (5-GGAUCAGUGCCU-
UUGGCUA-3), siRhoC-3 (5-GAAAGAAGCUGGUGAUCGU-3), on target 
plus siCONTROL non-targeting siRNA (D-001810-01, D-001810-02), 
siRac1-1 (5-AGACGGAGCUGUAGGUAAA-3), siRac1-2 (5-CGGCA-
CUGUCCCAACA-3), siROCK1-1 (5-GAAGAAACAUUCCCUAUUC-3),   
siROCK1-2 (5-GCCAAUGACUUACUUAGGA-3), siROCK2-1 (5-GCAA-
AUCUGUUAAUACUCG-3),  siROCK2-2  (5-CAAACUUGGUAAAGA-
AUUG-3), siFMNL3-1 (5-GCGAGGAGGUCACGAAAUC-3), siFMNL3-2 
(5-UGUCAGCCAUUCGAAUUAA-3), and FMNL1, FMNL2, and FMNL3 
pools (Dharmacon Smart pools). All siRNAs were initially tested for knock-
down of the protein. FMNL1-3 siRNA knockdown was tested by RT-PCR as 
described previously (Kitzing et al., 2010). Cells were reverse-transfected 
with 50–75 nM siRNA using Lipofectamine 2000 (Invitrogen) in complete 
medium without antibiotics. Medium was changed to complete medium 6 h 
after transfection. Where indicated, cells were starved in 1% or 0.1% FCS 
at least 12 h before the relevant assay.
Cell lysates for Western blot analysis were prepared 72 h after 
siRNA transfection using lysis buffer (50 mM Tris-HCl, pH 8, 0.5 mM EDTA, 
150 mM NaCl, and 1% Triton X-100 plus protease and phosphatase 
inhibitors cocktails). Lysates were resolved on 4–12% polyacrylamide gels 
(Invitrogen), transferred to PVDF membranes, and blotted with the indi-
cated antibodies.
The EGFP–-actin construct was a gift from B. Wehrle-Haller (Univer-
sity of Geneva, Geneva, Switzerland). A stable EGFP–-actin–expressing PC3 
cell line was created by the transfection of PC3 cells using Lipofectamine 
2000. Cells were selected in medium containing G418 until GFP–-
actin–expressing selected clones were visible. Clones were expanded and 
their morphology and migration was compared with control PC3 cells before 
being used.
Human FMNL3 cDNA cloned into pcDNA-DEST53 or pcDNA-DEST47 
(Invitrogen) to create GFP-FMNL3 or FMNL3-GFP, respectively, were provided 
by S. Wiemann (DKFZ, Heidelberg, Germany) and M. Teresa Herrera-Abreu 
(King’s College London, London, England, UK). FMNL2-GFP in pcDNA-DEST-
47 was a gift from K. Rottner (University of Bonn, Bonn, Germany). RhoA and 
RhoC cDNA with silent mutations that make them resistant to an siRNA for 
RhoA (siRhoA-1) or RhoC (siRhoC-1), respectively, were created using a Quik-
Change mutagenesis kit (Agilent Technologies) in expression vectors encod-
ing GFP-RhoA and myc-RhoC. Mouse GFP-ROCK1 cDNA in pcDNA-DEST53 
was a gift from C. Marshall and S. Kümper (Institute of Cancer Research,   
London, England, UK). Mouse ROCK2 cDNA in the pcDNA mRFP1 vector 
was described by Niault et al. (2009). Plasmids were transfected into PC3 
cells using JETPRIME reagent (PolyPlus transfections) 48 h after siRNA trans-
fection. Expression was assessed 15–20 h after DNA transfection.
Time-lapse microscopy
For bright field time-lapse microscopy, a fully motorized, multifield Nikon 
TE2000 microscope mounting an ORCA camera (Hamamatsu) and con-
trolled by the MetaMorph software was used. A 10×/0.3 NA Plan Fluor 
ELWD objective lens was used. For random migration studies, cells were 
seeded on a multiwell plate 48–52 h after transfection, and 8 h later, im-
ages were acquired at 37°C every 5 min for 14 h. More than 50 cells per 
siRNA condition from three different experiments were tracked 58–60 h   
after transfection for 12–14 h. Still images are from 72 h after transfec-
tion. Unless indicated, cells were imaged in medium containing 1% FCS. 
To visualize cell spreading, images were taken at high speed (one image 
per second) immediately after plating. For time-lapse microscopy of EGFP– 
-actin–expressing cells, cell images were acquired every 2 min for 3 h 
under similar conditions.
For chemotaxis assays, collagen IV precoated microslides (Ibidi) 
were used according to the manufacturer’s instructions using 10% FCS and 
20 ng/ml hepatocyte growth factor (HGF) as chemoattractants. Cell images 
were acquired every 5 min for 14 h. More than 200 cells per condition JCB • VOLUME 193 • NUMBER 4 • 2011   664
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Rho GTPase activity assays and GST pull-down
RhoA, RhoB, and RhoC activity assays were performed using Rho activa-
tion assay beads (GST-Rhotekin-RBD on glutathione beads) according to 
the manufacturer’s instructions (Cytoskeleton). Rac1 activity assays were 
performed using Rac1/Cdc42 assay reagent (GST-PAK1-PBD on gluta-
thione beads) according to the manufacturer’s instructions (Millipore).
GST-RhoA/C pull-down assays were performed with 5 µg of bacteri-
ally expressed GST-RhoA/C V14 protein or GST protein bound to glutathione-
Sepharose  beads  (GE  Healthcare).  They  were  incubated  with  293T  cell 
lysates overexpressing the indicated GFP-tagged FMNL3 or FMNL2 protein. 
Incubation was performed for 2 h at 4°C in lysis buffer (1% NP-40, 20 mM 
Tris-HCl, pH 8, and 130 mM NaCl). After washing the beads, proteins bound 
were resolved by electrophoresis and detected with the indicated antibodies.
Invasion assay and 3D culture
The transwell-based BD Biocoat invasion system (8 µm pore diameter; BD) 
was used to evaluate invasion through a Matrigel layer. The same BD inserts 
without the Matrigel coating were used as migration controls. To measure 
cell invasion, 10
5 cells in medium containing 0.1% FCS were added to the 
transwells, and 2 × 10
4 cells were used for migration. Medium containing 
1% FCS was used as an attractant in the lower chamber. Cells on the bottom 
of the coated transwell were counted after 24 h for invasion and 12 h for 
migration. The final time point was always 72 h after siRNA transfection.
To study morphology in 3D matrices, cells were reverse transfected 
with siRNA in suspension in complete medium and mixed after 6 h with a   
final concentration of 3 mg/ml of Matrigel or a mix of collagen I and Matri-
gel (2:1 mg/ml; BD). 72 h after transfection, cells were fixed with 4% para-
formaldehyde and stained for F-actin and DNA as described above. Z-stack 
confocal images were acquired on a confocal microscope (LSM 510 Meta; 
Carl Zeiss) with a 20× objective lens. Images shown are maximum intensity 
projections of a 100-µm z stack of images acquired every 5 µm.
The Oris 3D Invasion system (Platypus technologies) was used as 
described by the manufacturer. In brief, cells were seeded on a 96-well 
plate previously coated with a Matrigel or a collagen I/Matrigel mix (2:1) 
layer and with silicon stoppers covering the central area of the wells to cre-
ate a cell-free gap. The stoppers were removed after 12 h and cells were 
immediately overlaid with a thick layer of the same matrix. Cells were fixed 
and stained after 48 h and cells invading toward the gap in the center of 
the well were imaged.
Statistical analysis
For statistical significance analysis, one-way analysis of variance with a 
Dunn’s multiple comparison after test or unpaired t test were used. All sig-
nificances indicated are compared with siCsontrol condition unless other-
wise stated. All box and whisker plots boxes show median and 25th and 
75th percentiles; whiskers show the 95th percentile.
Online supplemental material
Fig. S1 and Fig. S2 show Rho isoform-specific knockdowns, morphology 
phenotypes, and Rac1 activity. Fig. S3 shows the effects of depleting Rho 
GTPases and downstream targets on cell morphology and migration, and 
FMNL3 overexpression experiments. Videos 1–3 show cell shape and mi-
gration after Rho isoform knockdown. Video 4 shows spreading of a RhoA-
depleted cell. Videos 5 and 6 show chemotaxis after different knockdowns. 
Videos 7 and 8 show FLIM acquired images. Online supplemental material is 
available at http://www.jcb.org/cgi/content/full/jcb.201011038/DC1.
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